LACunar Intervention Trial-3 (LACI-3): Assessment of efficacy and safety of cilostazol and isosorbide mononitrate to prevent adverse outcomes in patients with cerebral small vessel disease (lacunar) ischaemic stroke. What is LACI-3? LACI-3 study information Who can participate? Information for potential participants News About us. LACI-3 Hospitals Which UK hospitals are participating? Information for Researchers LACI-3 study information for researchers Trial Staff Login Access the LACI-3 database (authorised investigators only) Contact the Laci-3 trial team: laci-3@ed.ac.ukLACI-3 is managed by the the Trial Coordinating Centre:LACI-3 TrialCentre for Clinical Brain ScienceChancellor’s Building49 Little France CrescentEdinburghEH16 4SB This article was published on 2024-08-27
